You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TKI-resistant

Showing 1 - 25 of 5,911
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • +4 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Oct 25, 2022

    NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
    Dec 7, 2021

    Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

    Recruiting
    • Carcinoma, Non-Small Cell Lung
    • EGFR Gene Mutation
    • Gemcitabine platinum combined with erlotinib
    • Changsha, Hunan, China
      Hunan Province Tumor Hospital
    Feb 28, 2022

    EGFR Positive NSCLC Trial in China (APG-1252, Osimertinib Mesylate Tablets)

    Recruiting
    • EGFR Positive Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
    • +3 more
    Oct 27, 2021

    Non Small Cell Lung Cancer Trial in Shanghai (Tislelizumab, Carboplatin, Pemetrexed)

    Recruiting
    • Non Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 19, 2021

    Differentiated Thyroid Cancer Trial in China (AL2846 capsule)

    Recruiting
    • Differentiated Thyroid Cancer
    • AL2846 capsule
    • Guilin, Guangxi, China
    • +3 more
    Feb 27, 2023

    Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

    Active, not recruiting
    • Small Cell Carcinoma
    • +3 more
    • Palo Alto, California
    • +9 more
    May 12, 2022

    Hormone Refractory Prostate Cancer Trial in Seoul (TKI258)

    Completed
    • Hormone Refractory Prostate Cancer
    • Seoul, Chongro-ku, Korea, Republic of
    • +1 more
    Feb 16, 2021

    Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

    Recruiting
    • Lung Cancer, Non-small Cell
    • +4 more
    • Genomic profiles detection
    • circulating tumor DNA detection
    • Changsha, Hunan, China
      Department of Oncology, The Second Xiangya Hospital, Central Sou
    Oct 25, 2022

    Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III

    Terminated
    • Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
    • +9 more
    • Bintrafusp Alfa
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 4, 2022

    Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia Trial

    Completed
    • Chronic Phase Chronic Myeloid Leukemia
    • +4 more
    • Toronto, Ontario, Canada
      Princess Margaret Hospital / University Health Network
    Oct 29, 2020

    NSCLC, EGFR T790M, FDG-PET Trial in Essen (Osimertinib)

    Recruiting
    • NSCLC
    • +2 more
    • Essen, NRW, Germany
      Prof. Dr. med. Martin Schuler
    May 8, 2020

    Combination of Anlotinib and JS001 in EGFR-TKI Resistant

    Unknown status
    • NSCLC Stage IV
    • +3 more
      • Shanghai, China
        Shanghai Changzheng Hospital
      Oct 3, 2019

      Double-dose Furmonertinib in Treatment of Slow

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +3 more
      • (no location specified)
      Oct 31, 2023

      Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

      Recruiting
      • Non-small-cell Lung Carcinoma
      • Beijing, China
        Cancer Hospital, Chinese Academy of Medical Sciences
      May 11, 2023

      NSCLC Trial in Worldwide (pembrolizumab, pemetrexed, carboplatin)

      Active, not recruiting
      • Non-small Cell Lung Cancer
      • pembrolizumab
      • +4 more
      • Los Angeles, California
      • +157 more
      Aug 18, 2022

      Non Small Cell Lung Cancer Trial in Worldwide (Capmatinib, Nazartinib)

      Terminated
      • Non Small Cell Lung Cancer
      • Boston, Massachusetts
      • +18 more
      Jul 20, 2022

      GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

      Recruiting
      • Gastro-intestinal Stromal Tumor
      • Vena puncture for blood collection
      • Tumor biopsy
      • Amsterdam, Netherlands
      • +4 more
      May 17, 2022

      Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

      Recruiting
      • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jun 15, 2022

      Surgery in Gastrointestinal Stromal Tumors for Treatment, Tumor

      Recruiting
      • Gastric Cancer
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 30, 2023

        Trial (Olverembatinib)

        Available
          • (no location specified)
          Nov 10, 2022

          NSCLC, Apatinib, EGFR-TKI Trial in Shenzhen (Apatinib(Tab. 500mg/d) combined with EGFR-TKI(as previously))

          Unknown status
          • NSCLC
          • +2 more
          • Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
          • Shenzhen, Guangdong, China
            Shenzhen People's Hospital
          Apr 2, 2019

          Resistance to Tyrosine Kinase Inhibitor Osimertinib and

          Recruiting
          • Lung Cancer
          • Blood Samples
          • Lorient, France
          • +3 more
          Apr 26, 2022

          Prostate Cancer Trial in Houston (TK1258)

          Completed
          Has Results
          • Prostate Cancer
          • Houston, Texas
            University of Texas MD Anderson Cancer Center
          Aug 22, 2019